Human immunodeficiency virus type 1 infection, clinical trials and ethics in paediatrics

Acta Paediatrica, International Journal of Paediatrics, Supplement

Volumn 86, Issue 421, 1997, Pages 78-85

  De Martine, M ^a   Galli, L ^b   Amato, A Guarino ^b   Vierucci, A ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMED CONSENT; MEDICAL ETHICS; PATIENT SELECTION; PERINATAL INFECTION; PRIORITY JOURNAL; REVIEW; VERTICAL TRANSMISSION;

EID: 0030837458     PISSN: 08035326     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Chalmers TC. The clinical trial. Millbank Mem Fund 1981; 59: 325-39
2. Rosner F. The ethics of randomized clinical trials. Am J Med 1987; 82: 283-90
3. Tannisjo T. The morality of clinical research - a case study. J Med Philos 1994; 19: 7-21
4. Workshop del Gruppo di Studio della Società Italiana di Pediatria. Per una carta dei diritti del bambino con infezione da HIV. Riv Immunol Allerg Pediatr 1992; 2: 39-59
5. Simon RM. Design and conduct of clinical trials. In: DeVita Jr VT, Hellman S, Rosemberg SA, editors. Cancer principles and practice in oncology. 2nd ed. Philadelphia: JP Lippincott, 1982
6. Burlington DB. Statutory and regulatory framework for drug approval. J AIDS 1990; 3 Suppl 2: 4-9
7. Byar D. Design considerations for AIDS trials. J AIDS 1990; 3 Suppl 2: 16-9
8. Botti C, Vella S. Problemi bioetici nella sperimentazione di farmaci per l'infezione da HIV In: Cattorini P, editor. AIDS e Bioetica. Milano: Europa Scienze Umane Editrice, 1992
9. de Martino M, Tovo PA, Galli L, Gabiano C, Ceramia G, De Mattia D, et al. Human immunodeficiency virus type 1 infection and breast milk. Acta Paediatr Suppl 1994; 400: 51-8
10. Senturia YD, Ades AE, Peckham CS, Giaquinto C. Breast-feeding and HIV infection. Lancet 1987; 2: 400-1
11. World Health Organization. Consensus Statement from the WHO/ UNICEF Consultation on HIV Transmission and Breast-Feeding. Pediatr AIDS HIV Infect 1992; 5: 286-7
12. de Martino M, Tovo PA, Tozzi AE, Pezzotti P, Galli L, Livadiotti S, et al. HIV-1 transmission through breast-milk: appraisal of risk according to duration of feeding. AIDS 1992; 6: 991-7
13. de Martino M, Tovo PA. Quantifying the risk of HIV-1 transmission via breast-milk. AIDS 1993; 7: 134-5
14. Dunn DT, Newell ML, Ades AE, Pechkam CS. Risk of human immunodeficiency virus type 1 transmission through breastfeeding. Lancet 1992; 340: 585-8
15. Chalmers TC. The need for early randomization in the development of new drugs for AIDS. J AIDS 1990; 3 Suppl 2: 10-5
16. Spagnolo AG. Condizioni etiche per la sperimentazione di nuovi farmaci per l'AIDS. In: Cattorini P, editor. AIDS e Bioetica. Milano: Europa Scienze Umane Editrice, 1992
17. Volberding PA. Rationale for variations in clinical trials design in different HIV disease stages. J AIDS 1990; 3 Suppl 2: 40-4
18. Craven DE, Liebman HA, Fuller J, Hagerty C, Cooley TP, Saunders CA, et al. AIDS in intravenous drug users: issues related to enrollment in clinical trials. J AIDS 1990; 3 Suppl 2: 45-50
19. Cohen J. Women: absent term in the AIDS research equation. Science 1995; 269: 777-80
20. McNellis D. A view from Bethesda: NIH guidelines on the inclusion of women and minorities as subjects in clinical research. J Maternal Fetal Invest 1995; 5: 64
21. Arras JD. Non compliance in AIDS research. Hasting Center Rep 1990; 20: 24-32
22. Tovo PA, de Martino M, Gabiano C, Galli L, Caramia G, De Mattia D, et al. Epidemiology of HIV infection in Italy. Acta Paediatr Suppl 1994; 400: 15-8
23. Besch CL. Compliance in clinical trials. AIDS 1995; 9: 1-10
24. Pizzo PA. Practical issues and considerations in the design of clinical trials for HIV-infected infants and children. J AIDS 1990; 3 Suppl 2; 61-3
25. Galli L, de Martino M, Mannelli F, Vierucci A. Human immunodeficiency virus-type 1 screening in pregnancy: the magic wand to prevent perinatal infection in Europe? Eur J Pediatr 1993; 152: 458-9
26. Galli L, Tovo PA, de martino M, Gabiano C, Mannelli F, Tulisso S, et al. Impact of infection status in the father on the rate of HIV-1 transmission from an infected mother to her child. Pediatr AIDS HIV Infect 1993; 425-8
27. Principi N, Fontana M, Marchisio P, Giaquinto C, Plebani A, de Martino M, et al. Characteristics and evolution of family structure of children bom to HIV infected mothers. It J Paediatr 1994; 20: 153-9
28. Schabte B, Diaz T, Chu S Y, Caldwell B, Conti L, Alston O, et al. Who are the primary caretakers of children born to HIV-infected mothers? Results from a multistate surveillance project. Pediatrics 1995; 95: 511-5
29. McNutt B. The under-enrollment of HIV-infected foster care children in clinical trials and protocols and the need for corrective state action. Am J Law Med 1994; 20: 231-49
30. Lurie E, Bishaw M, Chesney M, Cooke M, Fernandes EL, Hearst N, et al. Ethical, behavioural, and social aspects of HIV vaccine trials in developing countries. JAMA 1994; 271: 295-301
31. Zelen M. A new design for randomized clinical trials. N Engl J Med 1979; 300: 1242-5
32. Kopelman L. Consent and randomized clinical trials: are there moral or design problems? J Med Philos 1986; 11: 317
33. Levine C, Neveloff Dubler N, Levin RJ. Building a new consensus: ethical principles and policies for clinical research on HIV/AIDS. Rev Hum Sub Res 1991; 13: 1-17
34. Mahler DM, Veatch RM, Sidel VW. Ethical issues in informed consent. JAMA 1982; 247: 481-5
35. Herxheimer A. The rights of the patient in clinical research. Lancet 1988; 2: 1128-30
36. Cassileth BR, Zupkis RV, Sutton-Smith K, March V. Informed consent - why are its goals imperfectly realized? N Engl J Med 1980; 302: 896-900
37. Lavelle-Jones C, Byrne DJ, Rice P, Cuscheri A. Factors affecting quality of informed consent. Br Med J 1993; 306: 885-90
38. Tovo PA, de Martino M, Gabiano C, Galli L, Cappello N, Ruga E, et al. Mode of delivery and gestational age influence the perinatal HIV-I transmission. J AIDS Hum Retrovirol 1966; 11: 88-94
39. Semprini AE, Castagna C, Ravizza M, Fiore S, Savasi V, Muggiasca ML, et al. The incidence of complications after caesarean section in 156 HIV-positive women. AIDS 1995; 8: 913-5
40. Minkoff HL, Moreno JD. Drug prophylaxis for human immunodeficiency virus-infected pregnant women: ethical considerations. Am J Obstet Gynecol 1990; 163: 1111-4
41. Connor EM, McSherry G. Immune-based interventions in perinatal human immunodeficiency virus infection. Pediatr Infect Dis J 1994; 13: 440-8
42. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus-type 1 with zidovudine treatment. N Engl J Med 1994; 331: 1173-80
43. de Martino M, Tovo PA, Galli L, Caselli D, Gabiano C, Mazzoni PL, et al. HIV-1 infection in perinatally exposed siblings and twins. Arch Dis Child 1991; 66: 1235-8
44. Gabiano C, Tovo PA, de Martino M, Galli L, Giaquinto C, Loy A, et al. Mother-to-child transmission of human immunodeficiency virus type 1: risk of infection and correlates of transmission. Pediatrics 1992; 90: 369-74
45. Editorial. Zidovudine for mother, fetus, and child: hope or poison. Lancet 1994; 344: 207-9
46. Rogers MF, Yaffe HW. Reducing the risk of maternal-infant transmission of HIV: a door is opened. N Eng J Med 1994; 331: 1222-3
47. DeRoo A, Colebounders R. Ethical issues in the use of zidovudine to reduce vertical transmission of HIV. N Engl J Med 1995; 332: 892
48. Morens DM. Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin Infect Dis 1994; 19: 500-12
49. Bayer R. Ethical challenges posed by zidovudine treatment to reduce vertical transmission of HIV. N Engl J Med 1994; 331: 1223-5
50. Huffman CA, Munson R. Ethical issues in the use of zidovudine to reduce vertical transmission of HIV. N Engl J Med 1995; 332: 891-2
51. Thea DM. Ethical issues in the use of zidovudine to reduce vertical transmission of HIV. N Engl J Med 1995; 332: 892
52. Koff WY, Hoth DF. Development and testing of AIDS vaccines. Science 1988; 241: 426-32
53. deMets DL. Data monitoring and sequential analysis - an academic perspective. J AIDS 1990; 3 Suppl 2: 124-33
54. Cooper EC. Active control equivalence trials. J AIDS 1990; 3 Suppl 2: 77-81
55. Whitley RJ, Soong S-J, Dolin R, Galasso G, Ch'ien LT, Alford CA. Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. N Engl J Med 1977; 297: 289-94
56. McCartney JJ. Encephalitis and ara-A: an ethical case study. Hastings Center Rep 1979; 8: 5-7
57. Fleming TR. Evaluation of active control trials in AIDS. J AIDS 1990; 3 Suppl 2: 82-7
58. Richman D, Itri L, Johnson MF, Eigo J. Design of clinical trials - active control trials. J AIDS 1990; 3 Suppl 2: 88-91
59. Amato DA, Lagakos SW. Consideration in the selection of endpoints for AIDS clinical trials. J AIDS 1990; 3 Suppl 2: 64-8
60. Moss AR. Laboratory markers as potential surrogates for clinical outcomes in AIDS trials. J AIDS 1990; 3 Suppl 2: 69-71
61. de Martino M, Tovo PA, Galli L, Gabiano C, Veglia F, Giaquinto C, et al. Features of children perinatally infected with HIV-1 surviving longer than 5 years. Lancet 1994; 3453: 191-5
62. de Martino M, Tovo PA, Galli L, Gabiano C, Cozzani S, Gotta C, et al. Prognostic significance of immunological changes in 675 infants perinatally exposed to human immunodeficiency virus. J Pediatr 1991; 119: 702-9
63. Editorial. Quality of life. Lancet 1991; 338: 350-1
64. Editorial. Quality of life and clinical trials. Lancet 1995; 346: 1-2
65. Cunningham WE, Bozzette SA, Hays RD, Kanouse DE, Shapiro MF. Comparison of health-related quality of life in clinical trial and non clinical trial human immunodeficiency virus-infected cohorts. Med Care 1995; 33 Suppl 4: 15-25
66. Balis FM, Poplack DG. Drug development and clinical pharmacology of antiretroviral drugs. In: Pizzo PA, Wilfert CM, editors. Pediatric AIDS: the challenge of HIV infected in infants, children and adolescents. 2nd ed. Baltimore: Williams and Wilkins, 1994
67. Tovo PA, de Martino M, Gabiano C, Cappello N, D'Elia R, Loy A, et al. Prognostic factors and survival in children with perinatal HIV-1 infection. Lancet 1992; 339: 1249-53
68. de Martino M, Tovo PA, Zuccotti GV, Galli L, Gabiano C, Fiocchi A, et al. Transferase values in infants at risk from human immunodeficiency virus type 1 perinatal infection. Pediatr Infect Dis J 1993; 12: 248-50
69. Galli L, de Martino M, Tovo PA, Gabiano C, Zappa M, Giaquinto C, et al. Onset of clinical signs in children with HIV-1 perinatal infection. AIDS 1995; 9: 455-61
70. de Martino M, Zappa M, Galli L, Rossi ME, Vierucci A. Does classificative system fit disease progression in perinatal human immunodeficiency virus infection? Acta Paediatr 1996; 85: 724-7
71. Boucher FD, Modlin JF, Weller S, Ruff A, Mirochnick M, Pelton S, et al. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J Pediatr 1993; 122: 137-44